SecBot SecBot
Biotech Drug Report Generated Nov 16, 2026

NDV-01

RLMD·RELMADA THERAPEUTICS, INC.
BULLISH
Drug Impact Rating7/10
Trial phase
Phase 2 completed; preparing for Phase 3 (SPECTRUM program)
Time to market
If the IND is cleared by early 2027 and Phase 3 SPECTRUM program proceeds smoothly, potential FDA submission could be 2029-2030, assuming positive pivotal data. The drug is still pre-Phase 3.
Why 7/10
The next hard catalyst is the NDV-01 IND submission, expected by year-end 2026 (within ~6 weeks). NDV-01 is Relmada's lead asset and primary value driver, but the IND submission is a regulatory milestone rather than a pivotal readout, and the company also has a second program (sepranolone).
Actionable Insight BULLISH

The next catalyst is the NDV-01 IND submission, which Relmada expects by year-end 2026 (about 6 weeks away). A successful IND clearance would allow the Phase 3 SPECTRUM program to begin, while any delay or FDA clinical hold would be sharply negative. The Q4 2026 corporate update will likely confirm the submission status.

Price Chart

Loading chart...

Executive Summary

NDV-01 is Relmada Therapeutics' (Nasdaq: RLMD) lead drug candidate for non-muscle invasive bladder cancer (NMIBC). Phase 2 data showed a 76% durable complete response rate at 12 months, with 86% of responders maintaining response at 18 months. The company is on track to submit an IND by year-end 2026 and initiate the Phase 3 SPECTRUM registrational program. The company raised $160M in a March 2026 PIPE and held $202.1M in cash as of Q3 2026, funding operations through 2029. Relmada previously lost ~80% of its value in December 2024 when its depression drug REL-1017 failed a Phase 3 futility analysis, making NDV-01 the company's primary value driver and a high-stakes pivot into oncology.

How It Works

NDV-01 is an investigational therapy for non-muscle invasive bladder cancer (NMIBC), a type of bladder cancer that has not spread into the deeper muscle layers. The exact mechanism of action is not publicly detailed in available sources, but it is being developed as a potential treatment for patients with high-risk NMIBC, an area with significant unmet need where the standard of care (BCG therapy) has high recurrence rates.

Trial Status

Phase 2 study in NMIBC completed with positive 12-month and 18-month durability data. The company is preparing to submit an IND by year-end 2026 and initiate the Phase 3 SPECTRUM registrational program, which includes two independent pathways for registration.

The Two-Sided Case

▲ Bull Case5
Phase 2 data showed a 76% durable complete response rate at 12 months in NMIBC, with 86% of 12-month complete responders maintaining response at 18 months, suggesting a durable treatment effect.
Relmada has a strong cash position of $202.1M (Q3 2026), expected to fund operations through 2029, removing near-term financing risk.
CEO Sergio Traversa and CFO Maged Shenouda collectively purchased ~$1.67M of stock in open-market transactions in September 2026, a strong insider conviction signal.
Institutional accumulation was broad in Q3 2026: Renaissance Technologies, FMR, Qube Research, Morgan Stanley, and others doubled or added to positions.
Analyst consensus is strongly bullish: 9 of 10 analysts rate Buy or Strong Buy, with a mean price target of $10.75 (155% upside from the $4.21 close on Nov 13, 2026).
▼ Bear Case4
Relmada has no approved products or revenue; it is entirely dependent on NDV-01 clinical trial success after its prior lead drug REL-1017 failed Phase 3 in depression (2022/2024), causing an 80% stock drop in December 2024.
The Phase 2 data showed two BCG-naive patients progressed to muscle-invasive disease at Month 15, a potential safety signal that could complicate FDA review.
The company has massively diluted shareholders: shares outstanding grew from ~30M at end-2024 to ~105M by May 2026, and an S-3 shelf registration filed in May 2026 signals potential further dilution.
NDV-01 has not yet entered Phase 3; the SPECTRUM program may fail to replicate Phase 2 efficacy or safety results, a common risk in oncology drug development.

Upcoming Catalysts

  • NDV-01 IND submission expected by year-end 2026 (Q4 2026)
  • FDA 30-day IND review period following submission (early 2027)
  • Initiation of Phase 3 SPECTRUM program (mid-2027)
  • Sepranolone IND submission also expected by year-end 2026

Source Filing

The SecBot filing or press-release report that triggered this drug report:

RELMADA THERAPEUTICS, INC. 8-K RLMD ·Originating report

Sources · 7

Hover a chip for the title
1 sec.gov2 sec.gov3 sec.gov4 sec.gov5 benzinga.com6 nasdaq.com7 msn.com